IRIS UniCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.467
NA - Nord America 2.019
EU - Europa 1.841
SA - Sud America 562
AF - Africa 59
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 6.956
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.944
SG - Singapore 1.055
CN - Cina 764
BR - Brasile 471
DE - Germania 432
IT - Italia 411
SE - Svezia 281
IN - India 160
VN - Vietnam 138
IE - Irlanda 130
FR - Francia 105
GB - Regno Unito 97
ID - Indonesia 92
UA - Ucraina 92
RU - Federazione Russa 68
FI - Finlandia 67
AR - Argentina 44
HK - Hong Kong 41
CA - Canada 37
KR - Corea 35
TR - Turchia 33
AT - Austria 29
BD - Bangladesh 29
MX - Messico 26
ES - Italia 24
NL - Olanda 24
JP - Giappone 23
ZA - Sudafrica 21
BE - Belgio 19
PL - Polonia 19
IQ - Iraq 16
IR - Iran 14
PK - Pakistan 14
VE - Venezuela 14
EC - Ecuador 10
LT - Lituania 10
CI - Costa d'Avorio 8
CL - Cile 8
MA - Marocco 8
PH - Filippine 8
CH - Svizzera 7
CO - Colombia 7
EG - Egitto 7
RO - Romania 7
SA - Arabia Saudita 7
IL - Israele 6
KZ - Kazakistan 6
CZ - Repubblica Ceca 5
JO - Giordania 5
KE - Kenya 5
AU - Australia 4
KG - Kirghizistan 4
PY - Paraguay 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
HN - Honduras 3
UZ - Uzbekistan 3
AL - Albania 2
AW - Aruba 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
ET - Etiopia 2
GR - Grecia 2
HU - Ungheria 2
MY - Malesia 2
OM - Oman 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
GD - Grenada 1
GE - Georgia 1
GY - Guiana 1
JM - Giamaica 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TO - Tonga 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 6.956
Salva come PNG Salva come JPEG
Città #
Singapore 460
Chandler 278
Ashburn 237
Hangzhou 188
Beijing 143
Dublin 126
Hyderabad 106
Rome 102
Hefei 99
Jakarta 80
New York 77
Wilmington 62
San Mateo 60
Los Angeles 59
Milan 56
Ho Chi Minh City 55
Jacksonville 47
Boston 46
Nanjing 41
Hong Kong 40
Munich 40
Moscow 37
São Paulo 35
Helsinki 34
Kent 32
Cattolica 31
Frankfurt am Main 31
Seoul 30
Princeton 29
Hanoi 28
The Dalles 27
Dallas 24
Houston 23
Zhengzhou 22
Redwood City 20
Dearborn 19
Santa Clara 19
Brussels 17
Buffalo 17
Lawrence 17
Seattle 17
Fairfield 16
Nanchang 16
Washington 16
Ann Arbor 15
Nuremberg 15
Tokyo 15
Vienna 15
Bremen 14
Izmir 13
Rio de Janeiro 13
Bari 12
Düsseldorf 12
London 12
Marseille 12
Mountain View 12
Phoenix 12
Woodbridge 12
Brooklyn 11
Chicago 11
Denver 11
Montreal 11
Atlanta 10
Orem 10
Toronto 10
Belo Horizonte 9
Boardman 9
Brasília 9
Johannesburg 9
Naples 9
Nürnberg 9
Paris 9
Porto Alegre 9
Portsmouth 9
Abidjan 8
Andover 8
Baghdad 8
Busto Arsizio 8
Lappeenranta 8
Mexico City 8
Richardson 8
Salvador 8
Stockholm 8
Turku 8
Bexley 7
Dhaka 7
Guangzhou 7
Hebei 7
Leawood 7
Málaga 7
Poplar 7
San Francisco 7
Warsaw 7
Amsterdam 6
Betim 6
Cairo 6
Cambridge 6
Chennai 6
Da Nang 6
Fortaleza 6
Totale 3.483
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 503
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 337
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 177
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 174
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 165
Sonographic imaging of urinoma 160
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 148
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 136
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 134
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 125
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 119
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 118
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 116
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 108
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 100
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 97
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 96
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 96
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 95
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 94
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 93
Recent progress in the use of pharmacotherapy for endometrial cancer 91
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 91
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 90
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 90
Sonographic imaging of urinoma. 90
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 90
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 85
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 85
Advanced and recurrent endometrial cancer: State of the art and future perspectives 84
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 83
PARP Inhibitors Resistance: Mechanisms and Perspectives 83
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 83
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 82
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 81
Endometrial carcinosarcoma 81
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 79
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 79
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 77
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 77
The role of artificial intelligence in managing multimorbidity and cancer 76
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 76
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 74
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 74
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 74
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 73
Clear cell carcinoma of the endometrium 73
Newly diagnosed ovarian cancer: Which first-line treatment? 72
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 70
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 70
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 70
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 69
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 69
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 69
A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study 68
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 68
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 67
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 66
Dostarlimab: From preclinical investigation to drug approval and future directions 61
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 59
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 59
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 59
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 57
Management of stage III and IVa uterine cancer 57
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 57
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 54
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 53
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 53
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 53
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 52
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 51
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 51
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 51
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 48
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 48
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 47
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 46
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup 44
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 43
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 41
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 41
Chemotherapy-free treatments: Are we ready for prime time? 37
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 36
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial 29
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 25
Totale 7.463
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021299 0 0 0 0 0 37 66 27 25 59 66 19
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/20251.700 35 40 121 61 97 59 86 74 206 229 378 314
2025/20262.136 548 133 306 502 609 38 0 0 0 0 0 0
Totale 7.463